FOXO Technologies Reports 63% Revenue Growth to $5.17M, Net Loss Widens to $1.45M in Q1
Summary
FOXO Technologies Inc. reported its first-quarter 2026 results, showing a significant 63% year-over-year revenue increase to $5.17 million, driven by hospital swing-bed volume and the Vector acquisition. However, the company's net loss to common stockholders widened considerably to $1.45 million from $0.79 million in the prior year, with diluted EPS declining to $(0.00). This earnings report follows the company's recent 10-K filing, which disclosed substantial doubt about its ability to continue as a going concern and issues with a critical reverse stock split. While the revenue growth indicates operational progress, the worsening net loss reinforces the severe financial challenges and liquidity concerns for this micro-cap OTC company. Traders will be closely watching for any developments regarding the company's ability to stem losses and address its going concern status.
At the time of this announcement, FOXO was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $306.3K. The 52-week trading range was $0.00 to $2.71. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.